ProCE Banner Activity

My Thoughts on Today’s Biggest Challenges in Myeloma Care

Clinical Thought
With advances in treatment and increased survival, we face new challenges in the care of patients with multiple myeloma. Here’s my take.

Released: October 22, 2019

Expiration: October 20, 2020

Share

Faculty

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Provided by

Provided by Purdue University College of Pharmacy
ProCE Banner

Supporters

Supported by educational grants from

Celgene

Janssen administered by Scientific Affairs

Karyopharm Therapeutics

Oncopeptides

Takeda Oncology

The Binding Site

Partners

IMF 2018

ProCE Banner

Faculty Disclosure

Primary Author

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji Kumar, MD, has disclosed that he has received consulting fees paid to his institution from AbbVie, Amgen, Celgene, Genentech, Janssen, Kite, MedImmune, Merck, and Takeda; funds for research support from AbbVie, Bristol-Myers Squibb, Celgene, Janssen, Kite, MedImmune, Merck, Novartis, Roche/Genentech, Sanofi, and Takeda; and fees for non-CME/CE services from Oncopeptides.